iData’s U.S. neurology devices market MedSuite covers 14 markets including procedure numbers and COVID-19 impacts. The MedSuite is a compilation of all reports related to a specific market. It is ideal for device manufacturers, product managers, marketing managers, and consultants looking for a detailed analysis of every market segment and sub-segment within a given market.

iData’s global neurology devices market MedSuite covers 15 markets including procedure numbers and COVID-19 impacts. The MedSuite is a compilation of all reports related to a specific market. It is ideal for device manufacturers, product managers, marketing managers, and consultants looking for a detailed analysis of every market segment and sub-segment within a given market.

iData’s European neurology devices market MedSuite covers 14 markets including procedure numbers and COVID-19 impacts. The MedSuite is a compilation of all reports related to a specific market. It is ideal for device manufacturers, product managers, marketing managers, and consultants looking for a detailed analysis of every market segment and sub-segment within a given market.

Liquid embolics currently on the market include N-butyl cyanoacrylate (NBCA) (TRUFILL®) and an ethylene-vinyl alcohol copolymer (Onyx®). These agents are injected through microcatheters and act like glue in abnormal blood vessels. When they contact blood they solidify and obstruct the vessel lumen therefore blocking the flow of blood through malformed blood vessels and reducing the risk of rupture. The surgeon performing the procedure must flush the catheter before and after injecting the NBCA to prevent the liquid agent from sticking to the catheter. Thus this procedure requires a highly skilled physician. This is often done prior to the removal of these vessels in order to simplify the surgical procedure.